DURHAM, N.C., Feb. 9 /PRNewswire/ -- Serenex, Inc., an integrated oncology-focused drug discovery and development company, announced today announced today that Dr. Richard Kent, chief executive officer, is scheduled to present at the BIO CEO & Investor Conference, taking place February 14th and 15th, 2006, at the Waldorf-Astoria in New York City.
On February 15 at 12:30, Dr. Kent will give a corporate presentation in the Conrad Suite. During the presentation Dr. Kent will provide an overview of the company including recent progress, strategy, and ongoing development programs.
A replay of the presentation will be available under the “News” section of the Serenex website (http://www.serenex.com) approximately 12 hours after the presentation for a period of 90 days.
About Serenex
Serenex is an integrated oncology-focused drug discovery and development company. The company’s mission is to improve the lives of cancer patients by developing proprietary therapeutic and supportive care products. Serenex’s clinical-stage program, SNX-1012, a product for chemotherapy and radiation- induced oral mucositis, is scheduled to begin Phase II clinical trials in early 2006. Additionally, Serenex has a novel pre-clinical small molecule inhibitor of Heat Shock Protein 90 (Hsp90) which is scheduled to begin clinical trials in early 2007. Hsp90 is a chaperone protein for a variety of oncogene products (such as Her2 and Raf) and their downstream signaling molecules (such as Akt and Erk). Serenex’s pipeline is powered by a proprietary screening platform which enables the company to profile compounds, in high throughput, against thousands of important therapeutic and toxicity targets simultaneously. By screening compounds in this manner Serenex is able to better understand specificity and toxicity issues, drive structure-activity relationships (SAR) and help determine mechanism of action. Since 2001 Serenex has worked with leading biotechnology and pharmaceutical companies in return for revenues and milestone payments. Website: http://www.serenex.com.
Serenex, Inc.
CONTACT: Ian Howes, CFO & Sr. V.P. Corporate Development of Serenex, Inc.,+1-919-281-6001, ihowes@serenex.com; or Michelle Linn of LinndenCommunications, +1-508-419-1555, linnmich@comcast.net
Web site: http://www.serenex.com/
